2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.Peer-Reviewed Original ResearchUterine serous carcinomaHER2/neuSerous carcinomaT-DXdTreatment optionsRecurrent uterine serous carcinomaDose-limiting side effectEffective treatment optionNew treatment optionsBone painRecurrent diseaseDurable responsesTrastuzumab deruxtecanCA 125Disease burdenSide effectsCarcinomaAntibody drugsTreatmentSignificant reductionDiseaseNeuExperimental treatmentsMetastaticPain
2007
Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor
Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor. Obstetrics And Gynecology 2007, 110: 518-520. PMID: 17666649, DOI: 10.1097/01.aog.0000267533.56546.c2.Peer-Reviewed Original ResearchConceptsUterine leiomyosarcomaAromatase inhibitorsTotal abdominal hysterectomyUterine leiomyosarcoma metastaticEstrogen receptor positivityPrimary uterine leiomyosarcomaMetastatic tumor nodulesAdjuvant platinumAnastrozole dailyLeiomyosarcoma metastaticAbdominal hysterectomyObjective responseReceptor positivityTumor depositsChemotherapeutic optionsDoxorubicin chemotherapySerial imagingTumor regressionTumor nodulesLeiomyosarcomaLungInhibitorsHysterectomyNulligravidaMetastatic